IBIO vs VRTX · rev $100.0K vs P/E 30, rev $3.33B
iBio, Inc. Common Stock (IBIO) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
IBIO currently screens at market cap $13.4M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the IBIO and VRTX stock pages for the full models.
Not investment advice.